175 related articles for article (PubMed ID: 30899983)
1. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
Natsume M; Shimura T; Iwasaki H; Okuda Y; Kitagawa M; Okamoto Y; Hayashi K; Kataoka H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1037-1046. PubMed ID: 30899983
[TBL] [Abstract][Full Text] [Related]
2. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
[TBL] [Abstract][Full Text] [Related]
3. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
[TBL] [Abstract][Full Text] [Related]
6. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
Van Cutsem E; Muro K; Cunningham D; Bodoky G; Sobrero A; Cascinu S; Ajani J; Oh SC; Al-Batran SE; Wainberg ZA; Wijayawardana SR; Melemed S; Ferry D; Hozak RR; Ohtsu A;
Eur J Cancer; 2020 Mar; 127():150-157. PubMed ID: 32014812
[TBL] [Abstract][Full Text] [Related]
7. Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.
Otsuka R; Iwasa S; Yanai T; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Hashimoto H; Sekiguchi M; Makino Y; Boku N; Yamaguchi M
Int J Clin Oncol; 2020 Apr; 25(4):595-601. PubMed ID: 31853798
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.
Izawa N; Sunakawa Y; Doi A; Arai H; Horie Y; Hirakawa M; Mizukami T; Ogura T; Tsuda T; Nakajima TE
Oncology; 2019; 97(2):94-101. PubMed ID: 31195391
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
[TBL] [Abstract][Full Text] [Related]
11. [The Clinical Effect of Ramucirumab in the Treatment of Advanced Gastric Cancer in Our Hospital].
Kenno S; Takahashi S; Noguchi K; Yamagami H; Ishizu H; Takahashi M
Gan To Kagaku Ryoho; 2018 Jan; 45(1):79-81. PubMed ID: 29362314
[TBL] [Abstract][Full Text] [Related]
12. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer].
Kimura Y; Makari Y; Mikami J; Kamigaki S; Ikejima A; Fujii C; Sawada G; Nakahira S; Yamamura J; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1193-1196. PubMed ID: 27760936
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
18. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
[TBL] [Abstract][Full Text] [Related]
19. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
Mizukami T; Miyaji T; Narita Y; Matsushima T; Ogura T; Miyagaki H; Kawabata R; Horie Y; Kawaguchi T; Muro K; Hara H; Yamaguchi T; E Nakajima T
Future Oncol; 2021 Jul; 17(19):2431-2438. PubMed ID: 33764163
[TBL] [Abstract][Full Text] [Related]
20. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
Kawai S; Fukuda N; Yamamoto S; Mitani S; Omae K; Wakatsuki T; Kato K; Kadowaki S; Takahari D; Boku N; Muro K; Machida N
BMC Cancer; 2020 Apr; 20(1):338. PubMed ID: 32316940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
